Zhengyan Li1, Yan Zhao2, Bo Lian2, Yezhou Liu2, Qingchuan Zhao3. 1. Department of Surgery, Xijing Hospital of Digestive Diseases, Fourth Military Medical University, No. 127 Changle West Road, Xi'an, 710032, China. Electronic address: lizhengyan01@sina.com. 2. Department of Surgery, Xijing Hospital of Digestive Diseases, Fourth Military Medical University, No. 127 Changle West Road, Xi'an, 710032, China. 3. Department of Surgery, Xijing Hospital of Digestive Diseases, Fourth Military Medical University, No. 127 Changle West Road, Xi'an, 710032, China. Electronic address: zhaoqc@fmmu.edu.cn.
Abstract
BACKGROUND: Multicenter randomized controlled trials (RCTs) and several meta-analyses have confirmed that laparoscopic gastrectomy (LG) is a safe and feasible procedure for patients with locally advanced gastric cancer (AGC) in terms of short-term outcomes. However, the long-term oncological outcomes of LG for AGC are still needed for further evaluation. This study aimed to compare the long-term oncological outcomes of LG with open gastrectomy (OG) for patients with AGC. METHODS: We performed a systematic literature search in various databases from January 1997 to August 2018. Studies comparing the long-term oncological outcomes between LG with OG were evaluated and data were extracted accordingly. We performed the meta-analysis using RevMan 5.3 software. RESULTS: Fifteen studies with 4494 patients (2273 in LG group and 2221 in OG group) were included. The 5-year overall survival (OS) rate (HR 0.95, 95% CI 0.86 to 1.05, P = 0.28), disease-free survival (DFS) rate (HR 0.93, 95% CI 0.81 to 1.06, P = 0.27), and recurrence rate (OR 0.87, 95% CI 0.72 to 1.04, P = 0.13) were comparable in LG and OG. Subgroup analysis showed the publication year, study region, sample size, extent of resection, extent of lymphadenectomy, retrieved lymph nodes, proportion of stage III, and patients with serosa-positive (pT4a) did not influence the estimates. CONCLUSIONS: For patients with AGC, LG is a feasible surgical procedure alternative to OG in terms of long-term oncological outcomes.
BACKGROUND: Multicenter randomized controlled trials (RCTs) and several meta-analyses have confirmed that laparoscopic gastrectomy (LG) is a safe and feasible procedure for patients with locally advanced gastric cancer (AGC) in terms of short-term outcomes. However, the long-term oncological outcomes of LG for AGC are still needed for further evaluation. This study aimed to compare the long-term oncological outcomes of LG with open gastrectomy (OG) for patients with AGC. METHODS: We performed a systematic literature search in various databases from January 1997 to August 2018. Studies comparing the long-term oncological outcomes between LG with OG were evaluated and data were extracted accordingly. We performed the meta-analysis using RevMan 5.3 software. RESULTS: Fifteen studies with 4494 patients (2273 in LG group and 2221 in OG group) were included. The 5-year overall survival (OS) rate (HR 0.95, 95% CI 0.86 to 1.05, P = 0.28), disease-free survival (DFS) rate (HR 0.93, 95% CI 0.81 to 1.06, P = 0.27), and recurrence rate (OR 0.87, 95% CI 0.72 to 1.04, P = 0.13) were comparable in LG and OG. Subgroup analysis showed the publication year, study region, sample size, extent of resection, extent of lymphadenectomy, retrieved lymph nodes, proportion of stage III, and patients with serosa-positive (pT4a) did not influence the estimates. CONCLUSIONS: For patients with AGC, LG is a feasible surgical procedure alternative to OG in terms of long-term oncological outcomes.
Authors: Zheng-Yan Li; Jie Chen; Bin Bai; Shuai Xu; Dan Song; Bo Lian; Ji-Peng Li; Gang Ji; Qing-Chuan Zhao Journal: Gastroenterol Rep (Oxf) Date: 2020-09-10
Authors: Pietro Maria Lombardi; Michele Mazzola; Vincenzo Nicastro; Simone Giacopuzzi; Gian Luca Baiocchi; Carlo Castoro; Riccardo Rosati; Uberto Fumagalli Romario; Luigi Bonavina; Fabio Staderini; Ines Gockel; Dario Gregori; Paolo De Martini; Monica Gualtierotti; Maria Danieli; Simona Beretta; Massimiliano Mutignani; Edoardo Forti; Giovanni Ferrari Journal: Front Oncol Date: 2022-03-17 Impact factor: 6.244
Authors: Giovanni Maria Garbarino; Giovanni Guglielmo Laracca; Alessio Lucarini; Gianmarco Piccolino; Paolo Mercantini; Alessandro Costa; Giuseppe Tonini; Giulia Canali; Edoardo Maria Muttillo; Gianluca Costa Journal: J Clin Med Date: 2022-06-22 Impact factor: 4.964